Notably, in clinical trials, Aurora B inhibitor AZD1152 (barasertib), as a single agent in acute myeloid leukemia (AML) (Löwenberg et al., 2011), showed reasonable responses in approximately 25% of the patients without a significant neuropathy. Here, AURKB is linked to acute myeloid leukemia.